AstraZeneca Departures Continue as Medical Chief Bohen Exits
- CMO joins drugmaker’s Mallon, Jallal in series of defections
- AstraZeneca executives targeted after strong approval record
Photographer: Daniel Acker/Bloomberg
This article is for subscribers only.
AstraZeneca Plc’s chief medical officer is leaving after less than four years at the company, adding to a wave of high-level defections amid a management shakeup at the U.K. drugmaker.
Sean Bohen, who’s also executive vice president for global medicines development, will part ways with Cambridge, England-based AstraZeneca after it completes the transition to the new structure unveiled last week, a spokesman said in emailed answers to questions.